Assessment of early response biomarkers in relation to long‐term survival in patients with HER2‐negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial

Pathologic complete response (pCR) is a predictor for favorable outcome after neoadjuvant treatment in early breast cancer. Modulation of gene expression may also provide early readouts of biological activity and prognosis, offering the possibility for timely response‐guided treatment adjustment. Th...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Int J Cancer
Main Authors: Kimbung, Siker, Markholm, Ida, Bjöhle, Judith, Lekberg, Tobias, von Wachenfeldt, Anna, Azavedo, Edward, Saracco, Ariel, Hellström, Mats, Veerla, Srinivas, Paquet, Eric, Bendahl, Pär‐Ola, Fernö, Mårten, Bergh, Jonas, Loman, Niklas, Hatschek, Thomas, Hedenfalk, Ingrid
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2017
Assuntos:
Tumor Markers and Signatures
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5765477/
https://ncbi.nlm.nih.gov/pubmed/28940389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.31070
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares